Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of intravitreal IBI302 in neovascular age-related macular degeneration
CTR20232229Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Sep 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of efdamrofusp alfa in exudative macular degeneration (2 arms), sponsored by InnoCare Pharma. Primary endpoint: Change from baseline in best corrected visual acuity score in the study eye. Started Sep 2023; status: active.
02
Drugs
efdamrofusp alfa
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20232229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232229.